Listener feedback on POET II, sham control trials in atrial fibrillation, ICDs in HCM, and agenda laundering are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Listener Feedback

POET II Response-Tailored or Standard-Duration ABX for Infectious Endocarditis

• POET I Trial https://www.nejm.org/doi/10.1056/NEJMoa1808312
• POET II Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2607887

II PVI-SHAM-AF trial Back in the News

• GAP-AF Trial https://www.ahajournals.org/doi/10.1161/circep.115.003337
• PVI-SHAM-AF Trial 10.1016/S0140-6736(26)01558-8 External Link
• Why Sham Studies Are a Sham in 2026 10.1016/j.hrthm.2026.09.056 External Link
• The Indispensable Role of Sham Controls in Evaluating Interventional Therapies 10.1016/j.hrthm.2026.10.001 External Link

III ICDs in HCM

• I CDs for the Prevention of SCD in High-Risk Patients with HCM https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.078597
• ICDs in HCM: Editorial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.079687

IV Agenda Laundering

• How Commercial “Agenda Laundering” Shapes Critical Care https://www.bmj.com/content/395/bmj-2026-100963

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.